Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
A registration statement on Form S-3 (File No. 333-211266) relating to these securities has been previously filed with and declared effective by the
The offering will be made only by means of a prospectus. A preliminary prospectus supplement describing the terms of the offering has been filed with the
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding
Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-pricing-of-public-offering-of-shares-of-common-stock-300374945.html
SOURCE
Investor Relations: Kristin Williams, Blueprint Medicines Corporation, 617-714-6674, kwilliams@blueprintmedicines.com; Media Relations: Rachel Hutman, W2O Group, 301-801-5540, rhutman@w2ogroup.com